Shots:

• The P-III (BRAVE-AA-PEDS) trial assessed baricitinib (2 or 4mg, QD, PO) vs PBO in 257 pts (12 to <18yrs.) with severe AA, where 89% had significant scalp hair loss, 65% had minimal/no eyebrow hair, & 57% had minimal/no eyelash hair with ClinRO of 2/3; next cohort (6 to <12yrs) enrollment to start in 2026   
• Trial at 36wks. showed 60% (4mg) & 36.9% (2mg) pts had ~50% SALT improvement vs 5.7%; 42.4% (4mg) & 27.4% (2mg) pts achieved ≥80% scalp coverage (1EP) vs 4.5%, while 36.5% (4mg) & 21.4% (2mg) had ≥90% coverage (SALT ≤10) vs 2.3%
• 50% (4mg) & 24.1% (2mg) pts on baricitinib had significant eyebrow regrowth vs 0%. For eyelash regrowth, 42.9% (4mg) & 25.5% (2mg) showed improvement vs 14% 

Ref: Eli Lilly | Image: Eli Lilly & Incyte

Related News:- Magnet Biomedicine Partners with Eli Lilly to Advance Molecular Glue Therapeutics in Oncology

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com